Amryt On Navigating Orphan Pricing And Reimbursement

 
• By Francesca Bruce
  
Pills
Amryt is aiming for prices that make a return on investment and which also reflect the value for patients
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access